Literature DB >> 11408937

Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.

K Smid1, C J Van Moorsel, P Noordhuis, D A Voorn, G J Peters.   

Abstract

The main mechanism of action of the anticancer drug gemcitabine is assumed to be incorporation of its triphosphate (dFdCTP) into DNA, resulting in inhibition of DNA polymerization, inhibition of DNA synthesis and repair. Another mechanism is inhibition of ribonucleotide reductase leading to imbalance in the deoxyribonucleotide (dNTP) pools. One assay to measure dNTP pools is based on oligonucleotide elongation mediated by DNA polymerase. Since the latter may be affected by dFdCTP, we studied the effect of 0.1-600 pmol dFdCTP on this assay; 10 pmol and more dFdCTP significantly increased the average dpm of the blank (absence of other dNTP) and that of the calibration line of dATP (1.4-1.6-fold); 0.1 pmol and more increased that of the standard dGTP curve significantly (1.1-1.8-fold); 10-75 pmol decreased that of dCTP while 75 and 100 pmol significantly increased that of dCTP (1.3-fold); 50 pmol significantly increased that of dTTP (1.3-1.5-fold). For dATP, dGTP and dTTP, a saturation was reached at 100 pmol dFdCTP, but not yet for dCTP. To minimize these effects, we added an excess of 200 pmol dFdCTP to all samples and calibration lines when measuring dNTP levels of gemcitabine treated samples. In this way the effects of gemcitabine on dNTP levels were studied in human A2780 ovarian, HT29 colon, K562 myelogenous leukemia, H322 non-small cell lung cancer cell lines and the murine lung cancer cell line Lewis Lung. In all cell lines, intrinsic dTTP pools (3-77 pmol/106 cells) were the highest, followed by dATP (1.5-31), dCTP (0.7-27) and (nd-14) dGTP. Exposure to 1 and 10 microM gemcitabine for 4-h concentration dependently decreased dATP 3-10-fold and dGTP to undetectable levels, but dCTP at most 3-fold, while dTTP increased. In conclusion, dFdCTP affects dNTP measurements with the DNA polymerase elongation assay, but its effect could be controlled by addition of similar amounts of dFdCTP to each assay.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408937

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.

Authors:  Ping Chen; Zhongfa Liu; Shujun Liu; Zhiliang Xie; Josephine Aimiuwu; Jiuxia Pang; Rebecca Klisovic; William Blum; Michael R Grever; Guido Marcucci; Kenneth K Chan
Journal:  Pharm Res       Date:  2009-03-17       Impact factor: 4.200

2.  FRET-based assay to screen inhibitors of HIV-1 reverse transcriptase and nucleocapsid protein.

Authors:  Kamal K Sharma; Frédéric Przybilla; Tobias Restle; Julien Godet; Yves Mély
Journal:  Nucleic Acids Res       Date:  2016-01-13       Impact factor: 16.971

3.  A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates.

Authors:  Peter M Wilson; Melissa J Labonte; Jared Russell; Stan Louie; Andrew A Ghobrial; Robert D Ladner
Journal:  Nucleic Acids Res       Date:  2011-05-16       Impact factor: 16.971

4.  Single-molecule detection of deoxyribonucleoside triphosphates in microdroplets.

Authors:  Boris Breiner; Kerr Johnson; Magdalena Stolarek; Ana-Luisa Silva; Aurel Negrea; Neil M Bell; Tom H Isaac; Mark Dethlefsen; Jasmin Chana; Lindsey A Ibbotson; Rebecca N Palmer; James Bush; Alexander J Dunning; David M Love; Olympia Pachoumi; Douglas J Kelly; Aya Shibahara; Mei Wu; Maciej Sosna; Paul H Dear; Fabian Tolle; Edoardo Petrini; Michele Amasio; Leigh R Shelford; Monica S Saavedra; Eoin Sheridan; Jekaterina Kuleshova; Gareth J Podd; Barnaby W Balmforth; Cameron A Frayling
Journal:  Nucleic Acids Res       Date:  2019-09-26       Impact factor: 16.971

5.  Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Authors:  Sean G Rudd; Nikolaos Tsesmetzis; Kumar Sanjiv; Cynthia Bj Paulin; Lakshmi Sandhow; Juliane Kutzner; Ida Hed Myrberg; Sarah S Bunten; Hanna Axelsson; Si Min Zhang; Azita Rasti; Petri Mäkelä; Si'Ana A Coggins; Sijia Tao; Sharda Suman; Rui M Branca; Georgios Mermelekas; Elisée Wiita; Sun Lee; Julian Walfridsson; Raymond F Schinazi; Baek Kim; Janne Lehtiö; Georgios Z Rassidakis; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Mats Heyman; Dan Grandér; Sören Lehmann; Thomas Lundbäck; Hong Qian; Jan-Inge Henter; Torsten Schaller; Thomas Helleday; Nikolas Herold
Journal:  EMBO Mol Med       Date:  2020-01-17       Impact factor: 12.137

Review 6.  The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.

Authors:  Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.